Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 57 for “"Tyrosine Kinase Inhibitors"”.
-
Tyrosine Kinase Inhibitors in Triple Negative Breast Cancer
… was to assess the potential role of selected inhibitors in TNBC, including the small molecule tyrosine kinases inhibitors of EGFR gefitinib and erlotinib, the monoclonal antibody against EGFR cetuximab, and the multi-target tyrosine kinase inhibitor dasatinib. Significantly higher EGFR …
-
CNS Penetration of Tyrosine Kinase Inhibitors in Mouse Models
… receptor (PDGFR), crenolanib, as examples of tyrosine kinase inhibitors currently tested for treatment of malignant glioma. Given the poor microdialysis probe recovery of these lipophilic molecules, we enhanced their recovery by including an affinity-based trapping agent, 10% …
-
SYNTHETIC AND MECHANISTIC STUDIES OF PRECIOUS METAL-MODIFIED TYROSINE KINASE INHIBITORS
Molecularly targeted therapies such as tyrosine kinase inhibitors (TKIs) make up an important class of oncology drugs. Targeting of cancer cells harboring oncogenic molecular targets, especially signaling kinases, with precision medicines, while sparing the majority of normal healthy cells, has led …
-
Development of novel receptor tyrosine kinase inhibitors by a chemocentric approach
… fewer programs being run in the manner. The AXL kinase is a receptor tyrosine kinase (RTK) and a member of the TAM family, along with MER and TYRO3. AXL has long been associated with numerous types of cancer. Having been first discovered in 1991 in acute myeloid leukaemia (AML), it has gone on to …
-
ACID-BASE INTERACTIONS IN AMORPHOUS SOLID DISPERSIONS: FORMULATION STRATEGY FOR TYROSINE KINASE INHIBITORS
Song, Yang. Ph.D., Purdue University, December 2015. Acid-base Interactions in
-
Perturbation Modeling for Molecular Design of Protein Tyrosine Kinase Inhibitors using Unsupervised Machine Learning
… transformations of small molecules to SRC kinase inhibitors using a combination of a generative learning technique called Variational Auto-Encoders and Unsupervised Machine Learning techniques. This study focuses specifically using the methods above to transform molecules from various …
-
Lokale Therapie der Sauerstoff-induzierten angioproliferativen Retinopathie im Mausmodell : Small Molecule Receptor Tyrosine Kinase Inhibitors
… vermittelt, die zur Familie der Rezeptor-Tyrosinkinasen gehören. Ein neues Konzept in der Therapie der angioproliferativen Retinopathie könnte die Blockade dieser Rezeptoren darstellen, um den Effekt von VEGF abzuschwächen oder gar aufzuheben. <br>Ziel dieser Arbeit war es, die Wirkung einer …
-
Development of Machine Learning Models for Generation and Activity Prediction of the Protein Tyrosine Kinase Inhibitors
… approaches for generation and scoring of novel kinase inhibitor molecules. We utilized a binary Random Forest classification model to develop a Machine Learning based scoring function to evaluate the generated molecules on Kinase Inhibition Likelihood. By training the model on several chemical …
-
EFFECT OF COMBINATION OF THE MAMMALIAN LIGNAN, ENTEROLACTONE, WITH TYROSINE KINASE INHIBITORS ON MARKERS OF HEPATIC FIBROSIS
… lignan, enterolactone (ENL), and selected tyrosine kinase inhibitors (TKIs) and to explore whether these effects involve peroxisome proliferator-activated receptor gamma (PPARγ), oxidative stress, and/or endoplasmic reticulum (ER) stress, known pathways of lignan and TKI action. A standard …
-
Exploring the role of IRF4 in the sensitivity of mantle cell lymphoma cells to Bruton's Tyrosine Kinase inhibitors
… of B-cell lymphoma. Therapy using Bruton’s tyrosine kinase (BTK) inhibitors has improved clinical outcomes but primary and secondary resistance to BTK inhibitor (BTKi) therapy affects more than half of MCL patients. Resistance most often arises through gene mutations in cells protected from …
-
Docetaxel uptake and modulation of P-gpmediated docetaxel efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines
… transport and examine the ability of three tyrosine kinase inhibitors (TKIs), gefitinib, erlotinib and lapatinib, to circumvent resistance to docetaxel, and other chemotherapeutic agents, arising from P-gp over-expression. A HPLC – based method was initially employed to quantify docetaxel …
-
An optical proteomic profile of the HER2 family in breast tumours and the effect of exposure to tyrosine kinase inhibitors
… of the effects of HER2-targeted therapy with the tyrosine kinase inhibitor (TKI) lapatinib, in vitro, and elucidation of the ensuing conformational changes may help understand the molecular activity of lapatinib and elucidate mechanisms of resistance. Clinical translation of this knowledge may …
-
Mechanism of resistance to tyrosine kinase inhibitors in philadelphia-positive acute lymphblastic leukaemia (all): from genetic alterations to impaired RNA editing
… overexpression of Ik6 impairs the response to tyrosine kinase inhibitors (TKIs) and contributes to resistance, an imatinib-sensitive Ik6-negative Ph+ ALL cell line (SUP-B15) was transfected with the complete Ik6 DNA coding sequence. The expression of Ik6 strongly increased proliferation and …
-
Συστηματική ανασκόπηση: αποτελεσματικότητα και ασφάλεια των αναστολέων κινάσης τυροσίνης στο χολαγγειοκαρκίνωμα / Efficacy and safety of tyrosine kinase inhibitors in cholangiocarcinoma: a comprehensive systematic review
… ORR από 15,6% έως 50%. Αντίθετα οι VEGFR/multikinase (αντιαγγειογενετικοί) αναστολείς καθώς και οι EGFR στοχευμένοι αναστολείς παρουσίασαν σημαντική ετερογένεια αποτελεσμάτων και κατά κανόνα χαμηλότερα ποσοστά ανταπόκρισης εκτός ορισμένων συνδυαστικών σχημάτων. Οι συνδυαστικές θεραπείες …
-
The effects of various combinations of different classes of anticancer drugs and tyrosine kinase inhibitors on the human MCF-7 and triple-negative MDA-MB 231 breast carcinoma cell lines
… and extracellular domains of the EGFR include tyrosine kinase inhibitors (TKIs), e.g., gefitinib and erlotinib and monoclonal antibodies, e.g., cetuximab and trastuzamab, that are amongst the most effective agents that are currently used together with chemotherapeutic agents in clinical …
-
Quantification of Major BCR-ABL1 Fusion Gene Transcripts for Monitoring Therapeutic Response to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia; Comparison of LightCycler t(9;22) Quantification Kit and BCR-ABL1 Mbcr IS-MMR Dx Kit.
BACKGROUND: CML is in >90% of cases characterized by the presence of the Philadelphia chromosome (Ph) and the corresponding fusion gene, BCR-ABL1. For disease monitoring, standardize BCR-ABL1 quantification and International Scale (IS) has been suggested, and this study is to compare IS-based …
-
Ocorrência de eventos adversos relacionados a inibidores de tirosina quinase de primeira e segunda geração : revisão de literatura
… and translated into protein BCR - ABL1. The tyrosine kinase inhibitors (TKIs) act by blocking the binding of ATP at the ABL1 kinase domain inhibi ts phosphorylation and resulting in cell death. Imatinib was the first inhibitor of protein tyrosine kinase BCR / ABL1 to be used and is considered …
-
Preclinical evaluation of pharmacological strategies designed to enhance the activity of established and novel anti-cancer drugs. Synopsis: Evaluation of pharmacological strategies designed to modulate the Warburg effect, enhance the activity of tyrosine kinase inhibitors and novel analogues of Temozolomide.
… and glutamine uptake. Using clinically approved tyrosine kinase inhibitors and Bortezomib, significant enhancement of chemosensitivity was observed when used in combination with inhibitors of lactate dehydrogenase (Gossypol) and pyruvate kinase dehydrogenase (Dichloroacetate). In contrast, …
-
Preclinical evaluation of pharmacological strategies designed to enhance the activity of established and novel anti-cancer drugs. Synopsis: Evaluation of pharmacological strategies designed to modulate the Warburg effect, enhance the activity of tyrosine kinase inhibitors and novel analogues of Temozolomide.
… and glutamine uptake. Using clinically approved tyrosine kinase inhibitors and Bortezomib, significant enhancement of chemosensitivity was observed when used in combination with inhibitors of lactate dehydrogenase (Gossypol) and pyruvate kinase dehydrogenase (Dichloroacetate). In contrast, …
Page 1 of 3